The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: Results from a controlled study

被引:27
|
作者
Saggese, G [1 ]
Federico, G [1 ]
Barsanti, S [1 ]
Fiore, L [1 ]
机构
[1] Univ Pisa, Osped S Chiara, Pediat Clin,Endocrine Unit, Dept Reprod Med & Pediat,Endocrine Unit, I-56125 Pisa, Italy
来源
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2001年 / 86卷 / 05期
关键词
D O I
10.1210/jc.86.5.1900
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To assess whether delaying puberty may improve final height in GH-deficient children with a poor height prediction at early puberty, we studied 24 girls with isolated GH deficiency until they reached their final height, in a controlled trial. Patients were taking recombinant human GH (r-hGH) substitutive therapy from 2.1 +/- 0.5 yr (0.1 IU/kg day sc) before entering the study, without showing any improvement in height prediction (149.6 +/- 2.9 vs.150.3 +/- 2.2 cm) on entering puberty. Fourteen girls agreed to add a GnRH agonist (GnRHa) to r-hGH, whereas the remaining 10 decided against it and served as controls. At the start of the study, girls treated with or without GnRHa had similar auxological characteristics (bone age, 10.9 +/- 0.6 vs. 10.7 +/- 1.3 yr; height SD score for chronological age, -1.87 +/- 0.3 vs. -1.82 +/- 0.2), including pubertal development. The GnRHa (long-acting D-Trp-6-GnRH) was given at 60 mug/kg im every 28 days for 1.9 +/- 0.9 yr, then patients continued the r-hGH at the same dosage (3.1 +/- 0.7 yr). At the end of the study, bone age was 16.2 +/- 0.3 yr in GnRHa-treated girls and 16.6 +/- 0.9 yr in controls. Bone maturation was significantly slower during GnRHa (1.4 +/- 0.2 yr), and height so score for bone age improved (-0.31 +/- 0.3) in comparison with controls (2.6 +/- 0.4 yr and -1.35 +/- 0.3 SD score; P < 0.001 and P < 0.0001, respectively). As a result, girls given the combined therapy reached a final height higher than that of controls (height SD score, -0.39 +/- 0.5 vs. -1.45 +/- 0.2; P < 0.0001) and also higher than their midparental height(-1.1 +/- 0.5; P < 0.0005). Controls reached their midparental height. In conclusion, our results demonstrate that slowing pubertal development with the administration of GnRHa for a limited time may improve final height in GH-deficient girls selected because of a poor height prediction at early puberty.
引用
收藏
页码:1900 / 1904
页数:5
相关论文
共 50 条
  • [1] The Effects of gonadotropin-releasing hormone analog and a combination of gonadotropin-releasing hormone analog and recombinant human growth hormone on adult height in girls with early puberty
    Hajzadeh, Ghodsieh
    Ghaemi, Norsrat
    Hadjzadeh, Mousa-Al-Reza
    Noroozi, Samaneh
    Morovatdar, Negar
    ADVANCED BIOMEDICAL RESEARCH, 2019, 8 (01): : 57
  • [2] Adult height in girls with idiopathic central precocious puberty with gonadotropin-releasing hormone agonist and recombinant human growth hormone treatment: a retrospective study
    He, Wenjuan
    Zhao, Sha
    Zhong, Yan
    You, Cheng
    He, Yi
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 434 - 434
  • [3] The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency
    Reiter, EO
    Lindberg, A
    Ranke, MB
    Price, DA
    Albertsson-Wikland, K
    Cowell, CT
    Bakker, B
    HORMONE RESEARCH, 2003, 60 : 68 - 73
  • [4] Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty
    Ah Young Cho
    Young Suk Shim
    Hae Sang Lee
    Jin Soon Hwang
    Scientific Reports, 13
  • [5] Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty
    Lee, Hae Sang
    Cho, Ah Young
    Shim, Young Suk
    Lim, Jung Sub
    Hwang, Jin Soon
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 2): : 344 - 344
  • [6] Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty
    Cho, Ah Young
    Shim, Young Suk
    Lee, Hae Sang
    Hwang, Jin Soon
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] The Effect of Gonadotropin-Releasing Hormone Agonist Treatment on Final Adult Height in Girls with Central Precocious Puberty
    Kim, Yoo-Mi
    Kim, Ja Hye
    Lee, Beom Hee
    Yoo, Han-Wook
    Choi, Jin-Ho
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [8] Can some growth hormone (GH)-deficient children benefit from combined therapy with gonadotropin-releasing hormone analogs and GH? Results of a retrospective study
    Tauber, M
    Berro, B
    Delagnes, V
    Lounis, N
    Jouret, B
    Pienkowski, C
    Oliver, I
    Rochiccioli, P
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03): : 1179 - 1183
  • [9] Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: Final height results
    Mul, D
    Bertelloni, S
    Carel, JC
    Saggese, G
    Chaussain, JL
    Oostdijk, W
    HORMONE RESEARCH, 2002, 58 (01) : 1 - 7
  • [10] Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty
    Lee, Hae Sang
    Yoon, Jong Seo
    Park, Kyu Jung
    Hwang, Jin Soon
    PLOS ONE, 2018, 13 (08):